Contract revenues and other operating income - Anti-Abeta Active Immunotherapy in AD - 2026 amendment agreement Takeda Pharmaceuticals, USA, Inc. (Details) SFr in Thousands, $ in Millions |
1 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
|
Apr. 30, 2026
CHF (SFr)
|
Apr. 30, 2026
USD ($)
|
Jun. 30, 2026
CHF (SFr)
|
Jun. 30, 2025
CHF (SFr)
|
Jun. 30, 2026
USD ($)
|
Dec. 31, 2025
CHF (SFr)
|
|
| Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||
| Contract revenue | SFr 16,232 | SFr 2,296 | ||||
| Short-term deferred contract revenue | 89,477 | SFr 83,706 | ||||
| Current trade receivables | 9,922 | |||||
| Anti-Abeta Active Immunotherapy in AD - 2026 amendment agreement Takeda Pharmaceuticals, USA, Inc. | ||||||
| Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||
| Value of milestone reached during the period | SFr 9,500 | $ 12.0 | ||||
| Contract revenue | 3,100 | |||||
| Short-term deferred contract revenue | 6,400 | |||||
| Current trade receivables | SFr 9,800 | $ 12.0 | ||||